16Bit is an AI medical software that helps detect patients at risk for osteoporosis. The company is in its early clinical stage and aims to discover unseen opportunities to improve health.
20/20 OptimEyes Technologies is a pre-clinical company looking to commercialize a mucoadhesive micelles formulation for drug delivery applications to improve patient outcomes.
AazeinTx is a clinical-stage pharmaceutical company developing a fast-acting oral treatment for acute asthma. The company’s asset carries potential expansion into other indications.
ABOzymes is a pre-clinical stage company that is developing an ex-vivo medical device to make blood types obsolete for organ transplants and blood transfusion.
Acorn Biolabs
We have entered the era of regenerative medicine. Clients are leveraging their own cells for anti-ageing skin and hair rejuvenation, in-patient trials are underway for cell and gene therapies, and scientists are developing solutions to grow organs on demand. As we age, so do our cells, and over time they lose their capability. Acorn has solved this problem, by allowing individuals to freeze their cells - stopping ageing and disease - through its patented, safe, and non-invasive live-cell collection, analysis, and cryopreservation service.
AmacaThera is a pre-IND staged company revolutionizing how therapeutics are delivered. Their technology is validated and compatible with a wide range of therapeutics classes.
Ananda Devices is a revenue generating diagnostics company that provides products and services to help pharmaceutical companies test safety and efficacy of medications 50x faster and 90x more cost efficiently using neurons derived from patients.
BreatheSuite is a digital health company with a remote monitoring product that empowers respiratory patients to live longer, healthier lives.
Cellular Analytics (University of Toronto) - The company develops autologous cell therapies using a proprietary cell isolation and processing platform that produces highly potent & effective cell-based products for immunotherapy that can be scaled for clinical use. The company utilizes its CytoFind technology to identify unique cellular markers that support the isolation of tumor reactive cells from both tumor tissue and circulation, enabling the next generation of autologous immunotherapies.
Cohesys is a pre-clinical medical device company that is creating a platform of advanced materials for repair, regeneration and therapeutic delivery applications; our first product is BoneTape – the world’s first ‘duct tape for bones’.
Cosm Medical is a medical device company at the early clinical stage that is bringing precision medicine to women suffering from pelvic floor disorders by commercializing the world’s first patient-specific pessary, Gynethotics.
CSTS Health is a pre-clinical biotechnology company developing precision oncology drugs using a novel platelet facilitated drug platform called Cytesia.
Cubresa is an early clinical staged medical device company that designs and builds PET inserts for MRI scanners for preclinical and clinical brain imaging, helping doctors and researchers understand and treat neurological diseases and disorders.
Cura Therapeutics is a pre-clinical stage company that is developing an innovative immunotherapy platform to treat a wide range of solid malignancies and infectious diseases.
Cyclica is a neo-biotech that is building the biotech pipeline of the future via partnerships and Cyclica’s unique polypharmacology and AI-enabled approach to multi-objective drug design platform.
Damona Pharmaceuticals (CAMH) - is pioneering the treatment of cognitive deficits in depression and aging. They developed best/first-in-class small molecules modulator of GABA, based on more than a decade of research in the human brain and animal models, led by Dr. Etienne Sibille, Founder, Acting CEO and CSO, Professor at the University of Toronto and Campbell Chair at CAMH. The lead program is to enter the clinic in 2023 with early readout for a proof-of-concept Phase 2A study for cognitive impairment in depression in 2025.
Diamond Therapeutics is working to develop safe and effective FDA, EMA, and Health Canada-approved pharmaceutical therapies for neuro-psychiatric conditions, starting with sub-perceptual psilocybin-based medicines.
Elarex is commercializing proprietary technology that stabilizes mRNA-LNP, virus, & protein therapeutics so pharmaceutical partners no longer need to be stored and shipped in a refrigerated or frozen cold chain.
Eye 3 is developing a next-generation drug screening platform that will detect drugs of abuse in oral fluid using proprietary sensor technology.
FE Pharmaceuticals is a game changing nontoxic, broad spectrum, anti-infective and anti-inflammatory polymer for drug resistant infections, sepsis, inflammation and cancer.
Feldan Therapeutics is a pre-clinical staged company that has developed an innovative and versatile technology, the Feldan Shuttle, allowing delivery of cargos intracellularly to reach master regulators of diseases thought to be undruggable.
Fluid Biomed is a pre-clinical medical device company commercializing the next generation of stents to treat brain aneurysms.
HDAX Therapeutics is a pre-clinical stage company focused on the development of targeted therapeutics for the safe and efficacious treatment of brain diseases.
Huron Digital Pathology is on a mission to democratize pathology and revolutionize disease diagnosis and treatment by unlocking the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data using AI-enabled image search.
Hyivy Health is a medical device company that creates a remote patient monitoring, pelvic rehab system for patients and their clinicians.
Immugenia is an early stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. Our proprietary technology allows for the CAR to be expressed selectively in T and NK cells in order to leverage their synergistic activity against cancer.
Inteligex is a biotechnology company developing precision stem cell therapies to reduce the tremendous costs associated with spinal cord injury and diseases of the central nervous system (CNS). Our two lead products, Intelicells and SMaRT Cells, are specifically engineered to regenerate acute and chronic CNS injuries using a patient's own cells.
MACH32 is a preclinical medical device company revolutionizing prehospital treatment for trauma victims by developing the first intramuscular autoinjector for tranexamic acid, a drug clinical proven to improve survival from trauma by 30% - an Epipen for trauma.
Managing Life is a company that helps with lowering the human and financial cost of chronic pain with its clinically validated digital solution, Manage My Pain.
Mediphage is a preclinical therapeutics company that is developing safe and redosable non-viral gene therapies based on its proprietary ministring DNA technology.
Medly (UHN) - The evidence-based Medly Program, developed at the University Health Network (UHN), is an AI enhanced expert system and integrated heart failure management protocol that optimizes heart failure patient access, delivering the highest quality care at the lowest cost.
MIMs (My Intelligent Machines), a revenue generating software company, provides biopharma companies with easy-to-implement and interactive augmented intelligence systems, to assist life scientists in the development of targeted therapies and biomarkers.
Mobio Interactive is a revenue generating software-as-a-medical device company. Their core solution prevents, measures, and treats mental illness, Mobio Interactive develops digital therapeutics personalized with objective and scalable biomarkers.
Nanology Labs is a Canadian biopharma company at the early clinical stage developing T-MX, a first-in-class nanomedicine that can improve therapeutic outcomes in the treatment of solid tumor cancers, leading to better survival and quality of life.
Nanovation Therapeutics is a early clinical stage gene therapy company that is building a dominant IP portfolio covering all aspects of lipid nanoparticle- and nucleic acid-based technologies to enable the development of next-generation gene therapies.
NERv Technology has developed smart post-operative monitoring solutions that improve patient’s post operative recovery process by enabling data-driven intervention and care.
Neurovine is a company with proprietary deep neuro analytics and machine learning algorithms that make the concussion recovery process visible to patients and clinicians while also providing real-time feedback that prevents recovery regression caused by overexertion.
NexPlasmaGen is a preclinical medical device company in the cold plasma oncology space with the mission to reduce cancer recurrence.
OPTT is a B2B SaaS virtual mental health platform targeting healthcare organizations. They equip clinicians with clinically validated digital care plans and analytical and AI capabilities to facilitate care delivery. OPTT can increase care capacity and personnel efficiency by up to 4X.
Quthero aims to disrupt skin care after dermatological procedures such as laser skin resurfacing, & microneedling, and to eliminate scarring post plastic surgery using patented hydrogels incorporating a unique evolutionary conserved peptide.
Raspberry Scientific is the only molecular diagnostics company aiming at detecting simultaneously every known coinfection associated with Lyme disease, thus helping patients in getting a complete diagnosis for faster recovery.
Ripple Therapeutics is a clinical stage therapeutics company focused on improving ophthalmic therapeutics with controllable, sustainable drug delivery.
Presenter: Wendy Naimark
Rna Diagnostics is a precision medicine company developing molecular diagnostic tools to effectively manage cancer treatment.
Serenity Bioworks is an early clinical stage company that is developing therapeutics from cellular stress pathways to improve outcomes for patients with severe autoimmune disorders.
SickKids Cystic Fibrosis Project – This research from Hospital for Sick Children and a LAB150-partnered drug discovery project is aimed at developing novel small molecule drugs for treating those cystic fibrosis (CF) patients with the highest remaining unmet need. Unlike most other CF therapies, this novel approach focuses on modulating a target protein other than the CFTR channel in a manner that can compensate for loss of CFTR function. The target protein has been extensively validated by lead SickKids researchers, Drs. Lisa Strug and Johanna Rommens, and collaborators as a major gene modifier of CF disease severity. This project combines the industry experience of LAB150 partner, Evotec SE, with the expertise of SickKids – a globally recognized centre of excellence for CF research and frontline patient care.
KaliDerm (Mount Sinai Hospital) - is a pre-company stage drug development program originating from the pioneering research on kallikrein proteases (KLKs) in the lab of Dr. Eleftherios Diamandis, under the supervision of lead scientist, Dr. Ioannis Prassas, at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute. KaliDerm’s lead project is focused on developing KLK small molecule inhibitors for the topical treatment of Netherton Syndrome (NS) – a severe inflammatory skin disorder and rare monogenic disease that is present in about 1 in 100,000 newborns. Broader applications are envisioned for additional inflammatory skin disorders, including atopic dermatitis and acne rosacea.
Specific Biologics is a discovery stage company located in JLABS @ Toronto with a mission to develop therapeutics using our new platform gene editing technologies.
ToeFx is a company has developed a made-in-Canada product that is a clinically proven light therapy treatment for toenail fungus.
Variational AI is an early stage AI platform for novel drug discovery used to generate internal small molecule assets to license to biopharma.
Vena Medical is an early clinical stage medical device company that is providing physicians with the world's smallest camera, capable of going inside veins and arteries to help them treat stroke.
Voyageur Pharmaceuticals Ltd is building a fully integrated radiology drug and device pharmaceutical company. We are currently fully integrating the barium contrast product line and upon completion, we will begin to fully integrate the iodine product line. By mining our feedstock ingredients barium and iodine, this allows our company to have the lowest cost inputs, results in higher margins and high growth rates.
Xpan is a preclinical medical device company developing miniaturized, less invasive yet expandable trocar access technology to make minimally invasive surgery safer & more efficient.
Zilia is a health technology company that provides actionable information based on the measurement of biomarkers in the eye to facilitate earlier diagnosis and improve the quality of life of patients.